/PRNewswire/ Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open.
Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed. | May 25, 2023